Some relief for industry as French reform bill nears final approval
This article was originally published in Scrip
The French bill on reforming the drug regulatory system is nearing final approval, offering industry the prospect of tougher obligations regarding comparative trials, side-effect reporting, benefit-risk monitoring and the declaration of links with its stakeholders such as doctors and patient groups.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.